Marcelo Bigal, Ventus Therapeutics CEO
February 9, 2022 10:34 AM ESTUpdated 02:49 PM
Financing

Up­dat­ed: RA Cap­i­tal and Soft­Bank head up the lat­est nine-fig­ure crossover, this time for Ven­tus. Will an IPO soon fol­low?

Max Gelman

Senior Editor

A biotech pre­vi­ous­ly backed by Ver­sant and GV is un­veil­ing its newest fi­nanc­ing round, com­ing with a slate of blue-chip in­vestors that could sig­nal an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times